These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Absence makes the HAART grow fonder. Gilden D GMHC Treat Issues; 1999 Feb; 13(2):1-4. PubMed ID: 11366113 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B; Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960 [TBL] [Abstract][Full Text] [Related]
5. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ; Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251 [TBL] [Abstract][Full Text] [Related]
6. Is Hydroxyurea for real? Mascolini M J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731 [TBL] [Abstract][Full Text] [Related]
7. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544 [TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. Paton NI; Aboulhab J HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247 [TBL] [Abstract][Full Text] [Related]
12. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132 [TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538 [TBL] [Abstract][Full Text] [Related]
14. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741 [TBL] [Abstract][Full Text] [Related]
15. Role of hydroxyurea during structured treatment interruptions. Foli A; Seminari E; Ravot E; Lisziewicz J; Lori F J Biol Regul Homeost Agents; 2002; 16(1):64-8. PubMed ID: 12003177 [TBL] [Abstract][Full Text] [Related]
16. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. Aiuti F; Mezzaroma I AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276 [TBL] [Abstract][Full Text] [Related]
17. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544 [TBL] [Abstract][Full Text] [Related]
18. The dissociation between virological and immunological responses to HAART. Jevtović D; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O Biomed Pharmacother; 2005 Sep; 59(8):446-51. PubMed ID: 16140494 [TBL] [Abstract][Full Text] [Related]
19. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea. Zala C; Salomón H; Cahn P Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880 [TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. Lori F; Lisziewicz J Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]